BUDGET IMPACT ANALYSIS OF DARATUMUMAB AS INDUCTION THERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED / REFRACTORY MULTIPLE MYELOMA FROM EGYPTIAN NATIONAL HEALTH INSURANCE ORGANIZATION PERSPECTIVE (HIO)
Author(s)
May Ahmed Samir Elkony, BSc1, Asmaa Saad Abourawash, BSc1, Mervat Matter, MD2, Raafat Abd Elfattah, MD3, Michael Abdelmalak Ghobrial, Sr., MSc4.
1Pharmacoeconomics Unit, Egyptian Drug Authority, Cairo, Egypt, 2Faculty of Medicine Cairo University, Cairo, Egypt, 3National Cancer Institute, Cairo, Egypt, 4Johnson & Johnson, Cairo, Egypt.
1Pharmacoeconomics Unit, Egyptian Drug Authority, Cairo, Egypt, 2Faculty of Medicine Cairo University, Cairo, Egypt, 3National Cancer Institute, Cairo, Egypt, 4Johnson & Johnson, Cairo, Egypt.
OBJECTIVES: Estimating the budget impact of gradual introduction of Daratumumab in combination with Lenalidomide and Dexamethasone (D-Rd), or Bortezomib and Dexamethasone (D-Vd), as an induction therapy for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM MM) who have received at least one prior therapy over 2-year time horizon from Egyptian national Health Insurance Organization perspective (HIO).
METHODS: A global dynamic budget impact analysis (BIA) model was validated and adapted from HIO perspective. The model is valuating-two-scenarios: a current scenario in which patients are receiving lenalidomide, bortezomib, and dexamethasone (VRD), while the new scenario assessed the adoption of daratumumab either as D-Rd or D-Vd. Clinical efficacy inputs adapted in the model were derived from CASTOR and POLLUX studies. The eligible patients for treatment were estimated using number of prevalent patients obtained from the HIO in addition to incident patients calculated using epidemiological data. Cost categories considered in the analysis included; treatment acquisition and administration, treatment-emergent adverse events, stem cell transplant, end of life care and subsequent therapy costs. Results were presented as incremental budget between the 2 scenarios over 2-year time frame for the financial year 2026.
RESULTS: The estimated budget impact of Daratumumab adoption as induction therapy for treatment of adult patients with RRMM over 2-year time horizon from HIO perspective was 701,788 USD (35,089,385 EGP) comprising 227,946 USD (11,397,304 EGP) in the first year and 473,841 USD (23,692,081 EGP) in the second year. The estimated cost- per treated patient 2-year period was 7,647.44 USD (382,371.94 EGP).
CONCLUSIONS: The analysis indicates that adopting daratumumab for the treatment of adult patients with RRMM increases treatment costs. However, these additional costs are partially offset by the higher rate of stem cell transplantation and improved survival, which translate into savings in end-of-life care costs.
METHODS: A global dynamic budget impact analysis (BIA) model was validated and adapted from HIO perspective. The model is valuating-two-scenarios: a current scenario in which patients are receiving lenalidomide, bortezomib, and dexamethasone (VRD), while the new scenario assessed the adoption of daratumumab either as D-Rd or D-Vd. Clinical efficacy inputs adapted in the model were derived from CASTOR and POLLUX studies. The eligible patients for treatment were estimated using number of prevalent patients obtained from the HIO in addition to incident patients calculated using epidemiological data. Cost categories considered in the analysis included; treatment acquisition and administration, treatment-emergent adverse events, stem cell transplant, end of life care and subsequent therapy costs. Results were presented as incremental budget between the 2 scenarios over 2-year time frame for the financial year 2026.
RESULTS: The estimated budget impact of Daratumumab adoption as induction therapy for treatment of adult patients with RRMM over 2-year time horizon from HIO perspective was 701,788 USD (35,089,385 EGP) comprising 227,946 USD (11,397,304 EGP) in the first year and 473,841 USD (23,692,081 EGP) in the second year. The estimated cost- per treated patient 2-year period was 7,647.44 USD (382,371.94 EGP).
CONCLUSIONS: The analysis indicates that adopting daratumumab for the treatment of adult patients with RRMM increases treatment costs. However, these additional costs are partially offset by the higher rate of stem cell transplantation and improved survival, which translate into savings in end-of-life care costs.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE230
Topic
Economic Evaluation, Health Policy & Regulatory, Health Technology Assessment
Topic Subcategory
Budget Impact Analysis
Disease
Oncology